Aeglea Biotherapeutics, Inc. (AGLE) 10K Annual Reports & 10Q SEC Filings

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Feb. 21, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	AGLE
Entity Registrant Name	AEGLEA BIOTHERAPEUTICS, INC.
Entity Central Index Key	0001636282
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Common Stock Shares Outstanding		65,395,159
Entity Public Float			$ 30.3
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Title of 12(b) Security	Common Stock, $0.0001 Par Value Per Share
Security Exchange Name	NASDAQ
Entity File Number	001-37722
Entity Tax Identification Number	46-4312787
Entity Address, Address Line One	805 Las Cimas Parkway
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Austin
Entity Address, Postal Zip Code	78746
City Area Code	512
Local Phone Number	942-2935
Entity Address, State or Province	TX
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Documents Incorporated by Reference	Portions of the Registrant’s Definitive Proxy Statement (“Proxy Statement”) relating to the 2023 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant’s 2022 fiscal year and is incorporated by reference into Part III of this Report.
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Austin, Texas

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1636282/000095017023005705/agle-20221231.htm

View differences made from one year to another to evaluate Aeglea Biotherapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aeglea Biotherapeutics, Inc..

Continue

Assess how Aeglea Biotherapeutics, Inc.'s management team is paid from their Annual Proxy

Aeglea Biotherapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

Legal

Other

Filter Subcategory:

All

Product

Expense

Other

Inside Aeglea Biotherapeutics, Inc.'s 10-K Annual Report:

Revenue - Product Highlight
In July 2020, we filed a shelf registration statement on Form S-3, or the 2020 Registration Statement, that was declared effective by the SEC for the potential offering, issuance and sale by us of up to $400.0 million of our common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and debt securities, subscription rights to purchase common stock and units consisting of all or some of these securities.

Financial - Shares Highlight
The shares of common stock and pre-funded warrants sold in the 2020 Public Offering were pursuant to a shelf registration statement on Form S-3, declared effective in February 2019 by the SEC for the potential offering, issuance and sale by us of up to $200.0 million of our common stock, warrants to purchase common stock, and other security types and subscription rights.
Revenue - Product Highlight
The net change in operating assets and liabilities of $1.8 million was primarily related to a $3.6 million increase in deferred revenue due to receiving a $21.5 million upfront payment under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA submission.
Financial - Expense Highlight
These increases will likely include higher costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.
Financial - Shares Highlight
We sold 15,442,303 shares of common stock and pre-funded warrants to purchase up to 13,610,328 shares of common stock in an underwritten public offering, or the 2020 Public Offering, for gross proceeds of $138.0 million, resulting in net proceeds of $129.0 million after deducting underwriting discounts, commissions, and offering costs.
Financial - Shares
In May 2022, we sold...Read more
Financial - Expense
We anticipate that our expenses...Read more
Other - Other
Under the terms of the...Read more
Financial - Expense
Additional offsets included a $1.2...Read more
Other - Other
Accordingly, based on recurring losses...Read more
Financial - Expense
The process of conducting the...Read more
Financial - Expense
General and administrative expenses increased...Read more
Other - Other
Accordingly, based on recurring losses...Read more
Legal - Other
Business and Macroeconomic Conditions The...Read more
Other - Other
Since we are a clinical-stage...Read more
Financial - Expense
Our research and development expenses...Read more
Financial - Expense
Research and development expenses increased...Read more
Revenue - Product
Such royalties are payable for...Read more
Other - Other
Contingent contractual obligations In June...Read more
Other - Other
The Restated License was amended...Read more
Revenue - Product
In addition, we are required...Read more
Other - Other
Changes in these estimates that...Read more
Revenue - Product
The estimates made on an...Read more
Revenue - Product
Components of Operating Results Revenue...Read more
Financial - Expense
Inputs, such as the services...Read more
Financial - Expense
We accrue for expenses resulting...Read more
Financial - Expense
The capitalized amounts are expensed...Read more
Revenue - Product
Also in May 2022, we...Read more
Financial - Expense
Additionally, we have incurred and...Read more
Revenue - Product
In the future, we may...Read more
Other - Other
In addition, we have based...Read more
Other - Other
These estimates are typically based...Read more
Other - Other
Based on the terms and...Read more
Other - Other
We may continue to experience...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aeglea Biotherapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10: Material Contract

Exhibit 21: Subsidaries Of The Registrant

Exhibit 23: Consents Of Experts And Counsel

Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32: Section 1350 Certification

Ticker: AGLE
CIK: 1636282
Form Type: 10-K Annual Report
Accession Number: 0000950170-23-005705
Submitted to the SEC: Thu Mar 02 2023 7:13:18 AM EST
Accepted by the SEC: Thu Mar 02 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/agle/0000950170-23-005705.htm

Aeglea Biotherapeutics, Inc. (AGLE) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

SEC Filings

AGLE Valuations

AGLE Annual Reports

AGLE Quarterly Reports

AGLE Corporate News